Table 2.
Summary of the clinical safety data in Study 002 and Study 001
Adverse event type | Study 002 (n = 21), n (%) | Study 001 (n = 9), n (%) |
---|---|---|
All adverse events | 21 (100) | 9 (100) |
Adverse events of grade 3 or higher | 18 (85.7) | 3 (33.3) |
Adverse events leading to death | 0 | 0 |
Serious adverse events | 1 (4.8) | 1 (11.1) |
Adverse events leading to treatment discontinuation | 0 | 0 |